FORAGER-1 trial: what clinicians have said so far
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
- NCT05614739 ↗
- Recruiting
- Eli Lilly and Company
- Deep size, estimated: 301+ verified statements once built
We haven't built an HCP commentary report on FORAGER-1 (vepugratinib (LOXO-435); vepugratinib (LOXO-435) plus pembrolizumab plus enfortumab vedotin; vepugratinib (LOXO-435) plus trastuzumab deruxtecan in advanced solid tumors with FGFR3 alterations) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Some of the questions raised in the 24 most recent indexed sources
Automated from the 24 newest of 27 indexed sources (Feb 2025 – Nov 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.
- Whether FGFR3 selectivity avoids erdafitinib's hyperphosphatemia, retinal and nail toxicities
- Whether adding vepugratinib to first-line enfortumab vedotin plus pembrolizumab adds benefit in FGFR3-altered disease
- Whether vepugratinib is active after progression on enfortumab vedotin plus pembrolizumab
Indexed commentary on FORAGER-1 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 20 posts on X, typically up to 88 once built | |
| 4 podcast episodes, typically up to 18 once built | |
| 3 YouTube videos, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- FORAGER-1: A Phase 1, Open-Label, Multicenter Study of Vepugratinib (LY3866288; LOXO-435) in Locally Advanced or Metastatic Solid Tumors Including Urothelial Cancer and Muscle Invasive Bladder Cancer With FGFR3 Alterations
- Phase
- Phase 1
- Status
- Recruiting
- Conditions
- Urinary Bladder Neoplasms; Neoplasm Metastasis; Ureteral Neoplasms
- Interventions
- Vepugratinib; Pembrolizumab; enfortumab vedotin; Trastuzumab Deruxtecan; Midazolam; Digoxin; Rosuvastatin
- Arms
- Phase 1a: Cohort A1 Vepugratinib Monotherapy Dose Escalation · Experimental
- Phase 1a: Cohort A2 Vepugratinib Monotherapy Dose Optimization · Experimental
- Phase 1b: Cohort B1, B2, B4, C1, and D1 Vepugratinib Monotherapy Dose Expansion · Experimental
- Phase 1b: Cohort B5 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin · Experimental
- Phase 1b: MIBC Cohort B6 Vepugratinib Plus Pembrolizumab Plus Enfortumab Vedotin · Experimental
- Experimental: Phase 1b: Cohort B7 Vepugratinib Plus Trastuzumab Deruxtecan · Experimental
- Phase 1b: NMIBC Cohort B8 Vepugratinib Monotherapy Dose Expansion · Experimental
- Phase 1b: Cohort D2 (Drug to Drug Interaction) · Experimental
- Enrollment
- 677 (estimated)
- Primary outcomes
- Overall Response Rate (ORR)
- Pharmacokinetics (PK) of Vepugratinib: Area Under the Concentration versus Time Curve (AUC)
- PK of Midazolam, Rosuvastatin, and Digoxin Administered Alone and in the Presence of Vepugratinib: Area Under the Concentration versus Time Curve (AUC[0-inf])
- Complete Response Rate (CRR) in Participants with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG IR NMIBC)
- Sponsor
- Eli Lilly and Company
- Start
- Jan 12, 2023
- Primary completion
- Jun 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05614739 · updated Nov 4, 2026